Judging Synthetic Biology Risks
As a member of the European Union Scientific Committees working group on Synthetic Biology, Riffyn is helping to define the field of Synthetic Biology and assess its benefits, risks, and research needs. This editorial outlines the work to-date and seeks public comment.
Tim Gardner is the Founder and the CEO of Riffyn. He was previously Vice President of Research & Development at Amyris, where he led the engineering of yeast strain and processes technology for large-scale bio-manufacturing of renewable chemicals. Tim has been recognized for his pioneering work in Synthetic Biology by Scientific American, the New Scientist, Nature, Technology Review, and the New York Times. He also served as an advisor to the European Union Scientific Committees and the Boston University Engineering Alumni Advisory Board. Tim enjoys hockey, running, mountain biking, and being beaten by his sons in almost everything.